8 April 2015
~ A Phase I/IIa study of IMCgp100: partial and complete durable responses with a novel first-in-class immunotherapy for advanced melanoma ~
(Oxford, UK, 8 April 2015) Immunocore Limited, a world-leading biotechnology company developing novel biological drugs to treat cancer, viral infections and autoimmune diseases, today announced that clinical trial data from the Phase I/IIa study of its lead programme IMCgp100, will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2015. The meeting will take place from 18-22 April 2015 in Philadelphia, USA.
IMCgp100, in the Phase I/IIa trial, showed partial and complete durable responses in patients with advanced melanoma.
The IMCgp100 clinical data will be presented by Mark Middleton MD, Professor of Experimental Cancer Medicine at the University of Oxford, and Principal Investigator for the study. Professor Middleton will present the data on April 19th 2015 at 2:05pm, in the Terrace Ballroom I (400 Level), Pennsylvania Convention Center.
Immunocore’s Phase I/IIa trial, conducted in the UK and USA, is designed to optimize the dosing regimen and maximise the efficacy of IMCgp100 while maintaining the favourable safety profile.
Please click on the link below to download the full Press Release: